Allergy Therapeutics (LON:AGY) Stock Price Down 5.8% – Should You Sell?

Allergy Therapeutics plc (LON:AGY) shares were down 5.8% during trading on Monday . The stock traded as low as GBX 10.29 and last traded at GBX 10.83. Approximately 127,653 shares traded hands during trading, a decline of 56% from the average daily volume of 293,300 shares. The stock had previously closed at GBX 11.50.

Allergy Therapeutics Stock Performance

The company has a market cap of £669.79 million, a PE ratio of -12.59, a PEG ratio of -30.70 and a beta of 0.83. The stock has a 50 day simple moving average of GBX 11.28 and a two-hundred day simple moving average of GBX 9.91. The company has a debt-to-equity ratio of -213.13, a current ratio of 1.28 and a quick ratio of 1.48.

Allergy Therapeutics (LON:AGY) last announced its earnings results on Monday, February 16th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. Allergy Therapeutics had a positive return on equity of 227.10% and a negative net margin of 72.91%. Equities analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.